Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly ...

Wall Street and the Fed will get more insight next week on inflation’s temperature and the economy. The government will ...

We recently published 10 Stocks with Eye-Popping Gains; 5 Jump to New Highs. Gilead Sciences, Inc. (NASDAQ:GILD) is one of ...

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

Gilead Sciences ( NASDAQ: GILD) was upgraded to Buy from Hold at Truist after the company raised full year sales and profit ...

Gilead Sciences Up Over 8%, on Track for Highest Close Since June 2015 — Data Talk Gilead Sciences, Inc. (GILD) is currently at $119.75, up $9.47 or 8.59% --Would be highest close since June 25, 2015, ...

Deborah Wafer, Executive Director of Public Affairs at Gilead Sciences, is working to address one of the most pressing health disparities in America: the gap between HIV risk and prevention access ...

Shares of Gilead Sciences Inc. GILD advanced 2.65% to $116.20 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.40% to ...

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents, the drugmaker said ...

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 3% in the afternoon session after its long-acting HIV prevention injection, lenacapavir, received a recommendation for ...